Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|January 10, 2023
- Pharmaceutical Technology's In the Lab eNewsletter, February 2023
- Volume 18
- Issue 2
Getinge Announces New BioProcess Control System
Author(s)Pharmaceutical Technology Editors
Getinge is launching Livit Flex, a bioprocess control system designed to help pharmaceutical and biotech products get to market faster.
Advertisement
Getinge, a Swedish medical technology company, announced the launch of the LivitFlex bioprocess control system. The system is designed to help pharmaceuticals and biotechnology products reach market faster.
According to a Dec. 15, 2022 press release, the LivitFlex speeds up development through system flexibility, smart sensor technology, and easy-to-use software functionalities. Additionally, by accessing and controlling multiple controllers from a PC or tablet in a laboratory, users can set up parallel experiments and monitor all data from one central location.
“Combining the flexibility of the Livit Flex controller, the intuitive Livit software, and Getinge bioreactors enables acceleration of R&D processes to make sure that pharmaceuticals and biotech products will ultimately end up faster where they are most needed – with the patients,” said Matthijs Niemeijer, head, Product Management Bioreactor Systems, Getinge, in the release.
Source:
Articles in this issue
over 3 years ago
Validating Cleaning Methods in Bio/Pharma Processesover 3 years ago
Scientific Laboratory Supplies Acquires C&M Scientificover 3 years ago
Nova Biomedical Launches Cell Density and Viability AnalyzerAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement